Evaluation Of Hepatic Impairment On AG-013736 Pharmacokinetics

A Phase 1 Study To Evaluate The Pharmacokinetics Of AG-013736 In Subjects With Impaired Hepatic Function

This study will evaluate the effects of mild and moderate impairment of hepatic function on the single-dose pharmacokinetics, safety and tolerability of AG-013736.

Inclusion Criteria:

• Diagnosis of reduced hepatic function (Child Pugh Classification A or B)
• Body Mass Index of 18-32 kg/m2

Exclusion Criteria:

• History of febrile illness within 5 days prior to first dose
• Any condition possibly affecting drug absorption (e.g. gastrectomy)
• Positive urine drug screen